PDCD1 and non-small cell lung carcinoma: The CCR was 93% (80% to 99%) in the discovery cohort Mel-PD1-A, 78% (63% to 88%) in cross-validation cohort Mel-PD1-B, and 68% (56% to 78%) in the second cross-validation cohort NSCLC-PD1 (figure 3d–f).